Vaxcyte, Inc.
PCVX
$30.65
$1.535.25%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | 75.00M |
| Gross Profit | -- | -- | -- | -- | -75.00M |
| SG&A Expenses | 28.56M | 22.99M | 21.47M | 19.89M | 17.53M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 162.17M | 139.92M | 152.98M | 114.47M | 196.68M |
| Operating Income | -162.17M | -139.92M | -152.98M | -114.47M | -196.68M |
| Income Before Tax | -137.08M | -103.12M | -128.70M | -95.02M | -180.80M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -137.08M | -103.12M | -128.70M | -95.02M | -180.80M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -137.08M | -103.12M | -128.70M | -95.02M | -180.80M |
| EBIT | -162.17M | -139.92M | -152.98M | -114.47M | -196.68M |
| EBITDA | -159.31M | -138.14M | -151.63M | -113.47M | -195.79M |
| EPS Basic | -1.01 | -0.83 | -1.10 | -0.85 | -1.76 |
| Normalized Basic EPS | -0.63 | -0.52 | -0.69 | -0.53 | -1.10 |
| EPS Diluted | -1.01 | -0.83 | -1.10 | -0.85 | -1.76 |
| Normalized Diluted EPS | -0.63 | -0.52 | -0.69 | -0.53 | -1.10 |
| Average Basic Shares Outstanding | 135.20M | 123.69M | 117.26M | 111.69M | 102.53M |
| Average Diluted Shares Outstanding | 135.20M | 123.69M | 117.26M | 111.69M | 102.53M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |